Floatz logo

Prednisone

EZB-MYC+ Diffuse Large B-Cell Lymphoma

The First Affiliated Hospital with Nanjing Medical UniversitySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the EZB-MYC+ Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Lenalidomide
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2CCC
Rituximab
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2CCC
Cyclophosphamide
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2CCC
Etoposide
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2CCC
(+)-Vincristine
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2CCC
Adriamycin
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2CCC

Same molecule, other indications

Prednisone is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
74 / 100
View asset →
diffuse large B-cell lymphomaActive
BBB
Indicative · Phase 4
74 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →